NO313982B1 - S(+)ibuprofenpartikler samt fremgangsmåte for fremstilling og anvendelse derav - Google Patents

S(+)ibuprofenpartikler samt fremgangsmåte for fremstilling og anvendelse derav Download PDF

Info

Publication number: NO313982B1
Authority: NO; Norway
Prior art keywords: jibuprofen; ibuprofen; particles; tablets; solvent
Prior art date: 1994-01-28

Application number

NO19962966A

Other languages

English (en)

Norwegian (no)

Other versions

NO962966L (no

NO962966D0 (no

Inventor

Torsten Moeller

Gerhard Hantich

Ernst Hesse

Original Assignee

Gebro Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-01-28

Filing date

1996-07-15

Publication date

2003-01-13

1996-07-15 Application filed by Gebro Pharma Gmbh filed Critical Gebro Pharma Gmbh

1996-07-15 Publication of NO962966L publication Critical patent/NO962966L/no

1996-07-15 Publication of NO962966D0 publication Critical patent/NO962966D0/no

2003-01-13 Publication of NO313982B1 publication Critical patent/NO313982B1/no

Links

238000000034 method Methods 0.000 title claims abstract description 45
239000002245 particle Substances 0.000 title claims abstract description 23
230000008569 process Effects 0.000 title claims abstract description 12
HEFNNWSXXWATRW-JTQLQIEISA-N dexibuprofen Chemical compound CC(C)CC1=CC=C([C@H](C)C(O)=O)C=C1 HEFNNWSXXWATRW-JTQLQIEISA-N 0.000 title abstract description 15
238000002360 preparation method Methods 0.000 title description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
238000004519 manufacturing process Methods 0.000 claims abstract description 15
238000003825 pressing Methods 0.000 claims abstract description 9
239000000126 substance Substances 0.000 claims abstract description 5
239000004480 active ingredient Substances 0.000 claims description 29
239000002904 solvent Substances 0.000 claims description 19
239000002775 capsule Substances 0.000 claims description 12
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 11
229960001680 ibuprofen Drugs 0.000 claims description 10
238000004090 dissolution Methods 0.000 claims description 8
238000003756 stirring Methods 0.000 claims description 8
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
238000011049 filling Methods 0.000 claims description 5
239000000155 melt Substances 0.000 claims description 5
238000002844 melting Methods 0.000 claims description 5
230000008018 melting Effects 0.000 claims description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
239000011230 binding agent Substances 0.000 claims description 3
238000003776 cleavage reaction Methods 0.000 claims description 3
230000003111 delayed effect Effects 0.000 claims description 3
229940079593 drug Drugs 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
238000001035 drying Methods 0.000 claims description 3
239000007903 gelatin capsule Substances 0.000 claims description 3
230000007017 scission Effects 0.000 claims description 3
229920002785 Croscarmellose sodium Polymers 0.000 claims description 2
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
239000001913 cellulose Substances 0.000 claims description 2
229920002678 cellulose Polymers 0.000 claims description 2
235000010980 cellulose Nutrition 0.000 claims description 2
238000001816 cooling Methods 0.000 claims description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
238000002347 injection Methods 0.000 claims description 2
239000007924 injection Substances 0.000 claims description 2
239000007788 liquid Substances 0.000 claims description 2
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
239000008108 microcrystalline cellulose Substances 0.000 claims description 2
229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
239000013543 active substance Substances 0.000 abstract description 2
239000003826 tablet Substances 0.000 description 25
239000000047 product Substances 0.000 description 19
239000013078 crystal Substances 0.000 description 6
239000003960 organic solvent Substances 0.000 description 5
238000010586 diagram Methods 0.000 description 4
239000000203 mixture Substances 0.000 description 4
238000012545 processing Methods 0.000 description 4
238000005054 agglomeration Methods 0.000 description 3
230000002776 aggregation Effects 0.000 description 3
238000011835 investigation Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
239000008363 phosphate buffer Substances 0.000 description 3
238000010008 shearing Methods 0.000 description 3
238000007873 sieving Methods 0.000 description 3
229910001220 stainless steel Inorganic materials 0.000 description 3
239000010935 stainless steel Substances 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
230000009471 action Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000011575 calcium Substances 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
239000008298 dragée Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000012467 final product Substances 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000007711 solidification Methods 0.000 description 2
230000008023 solidification Effects 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000007922 dissolution test Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
238000003912 environmental pollution Methods 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000007948 fast release tablet Substances 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
HEFNNWSXXWATRW-SNVBAGLBSA-N levibuprofen Chemical compound CC(C)CC1=CC=C([C@@H](C)C(O)=O)C=C1 HEFNNWSXXWATRW-SNVBAGLBSA-N 0.000 description 1
238000003760 magnetic stirring Methods 0.000 description 1
239000002075 main ingredient Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000010309 melting process Methods 0.000 description 1
239000004570 mortar (masonry) Substances 0.000 description 1
238000012856 packing Methods 0.000 description 1
238000010422 painting Methods 0.000 description 1
230000004526 pharmaceutical effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000010791 quenching Methods 0.000 description 1
230000000171 quenching effect Effects 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Polyurethanes Or Polyureas (AREA)

NO19962966A 1994-01-28 1996-07-15 S(+)ibuprofenpartikler samt fremgangsmåte for fremstilling og anvendelse derav NO313982B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
AT0015894A AT401871B (de)	1994-01-28	1994-01-28	Verfahren zur herstellung von s(+)-ibuprofen- partikeln mit verbesserten fliesseigenschaften und deren verwendung zur arzneimittelherstellung
PCT/AT1995/000014 WO1995020382A1 (fr)	1994-01-28	1995-01-26	Procede de production de particules d'ibuprofene s(+)

Publications (3)

Publication Number	Publication Date
NO962966L NO962966L (no)	1996-07-15
NO962966D0 NO962966D0 (no)	1996-07-15
NO313982B1 true NO313982B1 (no)	2003-01-13

Family

ID=3483086

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19962966A NO313982B1 (no)	1994-01-28	1996-07-15	S(+)ibuprofenpartikler samt fremgangsmåte for fremstilling og anvendelse derav

Country Status (20)

Country	Link
US (1)	US5869101A (fr)
EP (1)	EP0741565B1 (fr)
JP (1)	JP2840132B2 (fr)
AT (2)	AT401871B (fr)
AU (1)	AU689531B2 (fr)
CA (1)	CA2181810C (fr)
CZ (1)	CZ287998B6 (fr)
DE (1)	DE59508198D1 (fr)
DK (1)	DK0741565T3 (fr)
ES (1)	ES2146744T3 (fr)
FI (1)	FI112030B (fr)
GR (1)	GR3033841T3 (fr)
HU (1)	HU217798B (fr)
NO (1)	NO313982B1 (fr)
NZ (1)	NZ278551A (fr)
PL (1)	PL179095B1 (fr)
PT (1)	PT741565E (fr)
SI (1)	SI9520030A (fr)
SK (1)	SK282433B6 (fr)
WO (1)	WO1995020382A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI225402B (en)	1996-03-13	2004-12-21	Biochemie Gmbh	Auxiliary-free agglomerates
GB9613470D0 (en) *	1996-06-27	1996-08-28	Ciba Geigy Ag	Small solid oral dosage form
IT1301966B1 (it)	1998-07-30	2000-07-20	Zambon Spa	Composizioni farmaceutiche ad attivita' analgesica
CA2364342C (fr) †	1999-04-01	2011-02-01	Dsm N.V.	Agglomerats obtenus par cristallisation
DK1235558T3 (da) *	1999-12-09	2006-10-09	Reckitt Benckiser Healthcare	Sammenpresset tabletsammensætning, der omfatter et NSAID
KR100700721B1 (ko) *	2000-09-08	2007-03-27	지상철	안정성 및 용출율이 향상된 ｓ(+)-이부프로펜의 정제
GB0113839D0 (en) *	2001-06-07	2001-08-01	Boots Co Plc	Therapeutic agents
CN1889931A (zh) *	2003-12-04	2007-01-03	辉瑞产品公司	利用挤压器制备优选含泊洛沙姆和甘油酯的多重粒子阿奇霉素组合物的喷雾－冻凝方法
ATE399536T1 (de) *	2003-12-04	2008-07-15	Pfizer Prod Inc	Verfahren zur herstellung von pharmazeutischen multiteilchenförmigen produkten
US6984403B2 (en) *	2003-12-04	2006-01-10	Pfizer Inc.	Azithromycin dosage forms with reduced side effects
BRPI0416534A (pt) *	2003-12-04	2007-01-09	Pfizer Prod Inc	composições multiparticuladas com estabilidade melhorada
EP1694304A2 (fr) *	2003-12-04	2006-08-30	Pfizer Products Inc.	Formes de dosage multiparticulaire d'azythromycine obtenue par des procedes a base de liquide
WO2005053652A1 (fr)	2003-12-04	2005-06-16	Pfizer Products Inc.	Compositions medicamenteuses cristallines multiparticulaires contenant un poloxamere et un glyceride
WO2005053639A2 (fr) *	2003-12-04	2005-06-16	Pfizer Products Inc.	Formes multiparticulaires a liberation controlee produites avec des optimiseurs de dissolution
CA2549225A1 (fr) *	2003-12-04	2005-06-16	Pfizer Products Inc.	Procede d'atomisation/congelation faisant appel a une extrudeuse pour la preparation de compositions medicamenteuses cristallines multiparticulaires contenant de preference un poloxamere et un glyceride
CZ297830B6 (cs) *	2005-08-30	2007-04-11	I.Q.A., A. S.	Zpusob výroby jemne krystalické smesi obsahující nesteroidní protizánetlivé lécivo, jemne krystalická smes pripravitelná tímto zpusobem a pevný farmaceutický prostredek tuto smes obsahující
CN105963259A (zh) *	2016-05-25	2016-09-28	山东理工大学	一种采用常压过滤制备布洛芬微球的方法
CN109956860B (zh) *	2019-03-08	2022-03-01	天津大学	一种布洛芬球形晶体的制备方法
CN110041191A (zh) *	2019-04-30	2019-07-23	湖南九典宏阳制药有限公司	一种培比洛芬的纯化方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4086346A (en) *	1974-04-06	1978-04-25	Bayer Aktiengesellschaft	Preparation of melt-sprayed spherical phenacetin granules
JPS52111533A (en) *	1976-03-12	1977-09-19	Kanebo Ltd	Preparation of fine powder of ibuprophene
US4476248A (en) *	1983-02-28	1984-10-09	The Upjohn Company	Crystallization of ibuprofen
US4609675A (en) *	1984-08-17	1986-09-02	The Upjohn Company	Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
ATE50493T1 (de) *	1986-11-14	1990-03-15	Puetter Medice Chem Pharm	Ibuprofen enthaltendes arzneimittel.
GB8716975D0 (en) *	1987-07-17	1987-08-26	Boots Co Plc	Therapeutic agents
US5198568A (en) *	1988-04-07	1993-03-30	Sepracor, Inc.	Compounds useful in enzymatic resolution systems and their preparation
DE3833446A1 (de) *	1988-10-01	1990-04-05	Hoechst Ag	Verfahren zur herstellung von arzneimittelwirkstoff-partikeln mit verbesserten fliess-, lager- und formulierungseigenschaften sowie arzneimittel, die diese arzneimittelwirkstoff-partikeln enthalten
DE3833448A1 (de) *	1988-10-01	1990-04-12	Hoechst Ag	Verfahren zur gewinnung von ibuprofen fuer die direkttablettierung
HU209603B (en) *	1988-10-05	1994-09-28	Upjohn Co	Process for production of solid powders in finalydivided microcristallin form
JPH082781B2 (ja) *	1988-10-18	1996-01-17	嘉明川島	中空顆粒状医薬及びその製法
US5104656A (en) *	1989-06-16	1992-04-14	Seth Pyare L	Percutaneous treatment with a high potency non-steroidal anti-inflammatory agent
DE69108044T2 (de) *	1990-11-19	1995-07-06	Albemarle Corp	Verfahren zur verbesserung der fliessencharakteristik von kristallinem ibuprofen.
DE4122591C1 (en) *	1991-07-08	1993-02-18	Roland 8012 Ottobrunn De Bodmeier	Producing microcapsules of water insoluble polymer and active agent - includes dissolving or dispersing active agent in aq. polymer contg. gellable assistants
US5191114A (en) *	1991-10-09	1993-03-02	Sage Pharmaceuticals, Inc.	Process for enhancing the flow characteristics of ibuprofen
DE4140179C2 (de) *	1991-12-05	1995-12-21	Alfatec Pharma Gmbh	Akutform für ein Ibuprofen enthaltendes Arzneimittel

1994
- 1994-01-28 AT AT0015894A patent/AT401871B/de not_active IP Right Cessation
1995
- 1995-01-26 US US08/682,515 patent/US5869101A/en not_active Expired - Lifetime
- 1995-01-26 SI SI9520030A patent/SI9520030A/sl not_active IP Right Cessation
- 1995-01-26 AT AT95906207T patent/ATE191848T1/de active
- 1995-01-26 PL PL95315655A patent/PL179095B1/pl unknown
- 1995-01-26 AU AU14499/95A patent/AU689531B2/en not_active Ceased
- 1995-01-26 EP EP95906207A patent/EP0741565B1/fr not_active Expired - Lifetime
- 1995-01-26 CA CA002181810A patent/CA2181810C/fr not_active Expired - Fee Related
- 1995-01-26 JP JP7519783A patent/JP2840132B2/ja not_active Expired - Fee Related
- 1995-01-26 SK SK964-96A patent/SK282433B6/sk not_active IP Right Cessation
- 1995-01-26 DK DK95906207T patent/DK0741565T3/da active
- 1995-01-26 CZ CZ19962131A patent/CZ287998B6/cs not_active IP Right Cessation
- 1995-01-26 WO PCT/AT1995/000014 patent/WO1995020382A1/fr not_active Ceased
- 1995-01-26 ES ES95906207T patent/ES2146744T3/es not_active Expired - Lifetime
- 1995-01-26 DE DE59508198T patent/DE59508198D1/de not_active Expired - Lifetime
- 1995-01-26 HU HU9602013A patent/HU217798B/hu unknown
- 1995-01-26 PT PT95906207T patent/PT741565E/pt unknown
- 1995-01-26 NZ NZ278551A patent/NZ278551A/en not_active IP Right Cessation
1996
- 1996-07-15 NO NO19962966A patent/NO313982B1/no not_active IP Right Cessation
- 1996-07-16 FI FI962866A patent/FI112030B/fi not_active IP Right Cessation
2000
- 2000-06-30 GR GR20000401542T patent/GR3033841T3/el unknown

Also Published As

Publication number	Publication date
CZ213196A3 (en)	1996-10-16
US5869101A (en)	1999-02-09
NO962966L (no)	1996-07-15
FI112030B (fi)	2003-10-31
PL315655A1 (en)	1996-11-25
PL179095B1 (pl)	2000-07-31
SI9520030A (en)	1996-12-31
DE59508198D1 (de)	2000-05-25
EP0741565B1 (fr)	2000-04-19
GR3033841T3 (en)	2000-10-31
CZ287998B6 (cs)	2001-03-14
AT401871B (de)	1996-12-27
CA2181810C (fr)	2000-10-24
ES2146744T3 (es)	2000-08-16
ATA15894A (de)	1996-05-15
WO1995020382A1 (fr)	1995-08-03
SK96496A3 (en)	1997-01-08
DK0741565T3 (da)	2000-09-04
NZ278551A (en)	1997-10-24
EP0741565A1 (fr)	1996-11-13
JPH09503522A (ja)	1997-04-08
HU9602013D0 (en)	1996-09-30
NO962966D0 (no)	1996-07-15
FI962866L (fi)	1996-07-16
ATE191848T1 (de)	2000-05-15
JP2840132B2 (ja)	1998-12-24
SK282433B6 (sk)	2002-02-05
HUT74853A (en)	1997-02-28
AU1449995A (en)	1995-08-15
AU689531B2 (en)	1998-04-02
PT741565E (pt)	2000-09-29
HU217798B (hu)	2000-04-28
FI962866A0 (fi)	1996-07-16

Legal Events

Date	Code	Title	Description
2014-08-25	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO313982B1 (no)	2003-01-13	S(+)ibuprofenpartikler samt fremgangsmåte for fremstilling og anvendelse derav
CS247079B2 (en)	1986-11-13	Production method of the divisable tablet with retarded realising of its effective substance
WO1984002843A1 (fr)	1984-08-02	Procede de preparation de compositions pharmaceutiques a liberation entretenue ayant une teneur elevee en ingredients actifs
Paradkar et al.	2003	Preparation and evaluation of ibuprofen beads by melt solidification technique
US5512302A (en)	1996-04-30	Pharmaceutical process using starch
Hansen et al.	2021	Improving flowability and reducing storage agglomeration of metformin hydrochloride through QESD crystallization
EP0841062B1 (fr)	2004-11-24	Procede de production d'une preparation granulaire
CN112351772B (zh)	2023-05-16	颗粒尺寸不一致的原料药颗粒的处理方法
KR20030024833A (ko)	2003-03-26	시탈로프람을 함유하는 약학 조성물
TW202039488A (zh)	2020-11-01	具改善性質之｛４，６－二胺基－２－［５－氟－１－（２－氟芐基）－１Ｈ－吡唑並［３，４－ｂ］吡啶－３－基］嘧啶－５－基｝胺基甲酸甲酯活性化合物產物、其製造及調配物
Nokhodchi et al.	2007	An improvement of physicomechanical properties of carbamazepine crystals
EP1069896A1 (fr)	2001-01-24	Medicaments galeniques a base de carvedilol
EP2170285B1 (fr)	2014-10-01	Procédé de préparation de compositions solides à libération contrôlée contenant de l'oxcarbazépine, et compositions obtenues par ce procédé
US2689202A (en)	1954-09-14	Process of grinding frozen vitamin a material
JP4467230B2 (ja)	2010-05-26	有機物の造粒方法
JPH09309829A (ja)	1997-12-02	ニトレンジピン含有経口投与製剤およびその製造法
Gahoi et al.	2011	Influence of novel ‘dispersed fusion technique’on dissolution and pharmacotechnical properties of pharmaceutical solid dispersion
EP0950050A1 (fr)	1999-10-20	Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues
JP2006522763A (ja)	2006-10-05	顆粒形態のｂ／ｃ変態型リボフラビンの調製方法
JPS6270322A (ja)	1987-03-31	医薬製剤
Chavda et al.	0	Spherical Crystallization: Making Biopharmaceutical Parameters Tilorable
TW200522943A (en)	2005-07-16	Fine crystallites and a pharmaceutical composition comprising them